References
- Patel HRH, Mould T, Joseph JV, Delaney CP. Pelvic Cancer Surgery: Modern Breakthroughs and Future Advances. Springer 2015
- Voskoboynik M, Staffurth J, Malik Z, et al. ‘Charting a new course for prostate cancer’ – currying favour for docetaxel in hormone sensitive metastatic prostate cancer. Expert Rev Anticancer Ther 2014;14(11):1253-6
- Hu B, Goldkorn A. Circulating tumor cells in prostate cancer: a better predictor of survival than prostate specific antigen? Expert Rev Anticancer Ther 2014;14(11):1257-60
- Su MZ, Kneebone AB, Woo HH. Adjuvant versus salvage radiotherapy following radical prostatectomy: do the AUA/ASTRO guidelines have all the answers? Expert Rev Anticancer Ther 2014;14(11):1265-70
- de Moraes FY, de Siqueira GMS, Abreu CECV, et al. Hypofractioned radiotherapy in prostate cancer: is it the next step? Expert Rev Anticancer Ther 2014;14(11):1271-6
- Sountoulides P, Moutzouris G. Prostate-specific antigen screening, why have the guidelines changed? Expert Rev Anticancer Ther 2014;14(11):1277-81
- Bracarda S, Sisani M, Marrocolo F, et al. Clinical implications for a treatment algorithm and differential indication to hormone therapy and chemotherapy options in metastatic castrate-resistant prostate cancer: a personal view. Expert Rev Anticancer Ther 2014;14(11):1283-94
- Chism DD, De Silva D, Whang YE. Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Rev Anticancer Ther 2014;14(11):1369-78
- Patel VH. Nutrition and prostate cancer: an overview. Expert Rev Anticancer Ther 2014;14(11):1295-304
- Galazi M, Rodriguez-Vida A, Ng T, et al. Precision medicine for prostate cancer. Expert Rev Anticancer Ther 2014;14(11):1305-15
- Costa-Pinheiro P, Patel HRH, Henrique R, Jerónimo C. Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer. Expert Rev Anticancer Ther 2014;14(11):1349-58
- Rodrigues Â, Freitas R, Nogueira-Silva P, et al. Biopsy sampling and histopathological markers for diagnosis of prostate cancer. Expert Rev Anticancer Ther 2014;14(11):1323-36
- Shah TT, Ahmed H, Kanthabalan A, et al. Focal cryotherapy of localised prostate cancer: a systematic review of the literature. Expert Rev Anticancer Ther 2014;14(11):1337-47
- Valerio M, Emberton M, Barret E, et al. Health technology assessment in evolution – focal therapy in localised prostate cancer. Expert Rev Anticancer Ther 2014;14(11):1359-67
- Müller S, Grønning LE, Nilson FS, et al. Robotic and minimal access surgery: technology and surgical outcomes of radical prostatectomy for prostate cancer. Expert Rev Anticancer Ther 2014;14(11):1317-21
- Rodney S, Shah TT, Patel HRH, Arya M. Key papers in prostate cancer. Expert Rev Anticancer Ther 2014;14(11):1379-84
- Frame I. Biography: Dr Iain Frame, director of research, prostate cancer, UK. Expert Rev Anticancer Ther 2014;14(11):1261-4